Bio­gen boasts PhII win in lu­pus — will any­one turn their head from Alzheimer's to no­tice?

As the gaze on ad­u­canum­ab in­ten­si­fies in the runup to Bio­gen’s hot­ly-an­tic­i­pat­ed da­ta pre­sen­ta­tion at an Alzheimer’s con­fer­ence this week, the biotech is of­fer­ing some re­lief in the form of pos­i­tive Phase II re­sults for a lu­pus drug.

Dubbed BI­IB059, the lit­tle known an­ti­body de­liv­ered clean hits on the pri­ma­ry end­points for both parts of the study, in­volv­ing pa­tients with cu­ta­neous lu­pus ery­the­mato­sus and sys­temic lu­pus ery­the­mato­sus, re­spec­tive­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER